ACM
SLNO

ADAR1 Capital Management’s Soleno Therapeutics SLNO Stock Holding History

ADAR1 Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$3.57M – 234
2025
Q1 		$3.57M Buy
+50,000
New +$2.43M 0.66% 45
2024
Q1 		– Sell
-1,100
Closed -$44.3K – 288
2023
Q4 		$44.3K Buy
+1,100
New +$31.3K 0.02% 118

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

ADAR1 Capital Management's SLNO Position: Q1 2026 in Review

ADAR1 Capital Management increased its Soleno Therapeutics (SLNO) stake by 12% in Q1 2026, buying an estimated $196K and bringing the position to 46,830 shares worth $1.57M. The position accounts for 0.09% of the portfolio, ranked #128.

ADAR1 Capital Management first reported a position in SLNO in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.94M in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • ADAR1 Capital Management held 46,830 shares of Soleno Therapeutics worth $1.57M as of Q1 2026.
  • ADAR1 Capital Management bought 5,000 Soleno Therapeutics shares in Q1 2026, an estimated $196K.
  • Soleno Therapeutics made up 0.09% of ADAR1 Capital Management's portfolio in Q1 2026, its #128 holding.
  • ADAR1 Capital Management first reported a position in Soleno Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • ADAR1 Capital Management's Soleno Therapeutics position peaked at $1.94M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.